Robert J. Glynn, PhD, ScD
Professor of Medicine, Harvard Medical School
Senior Biostatistician, Brigham and Women’s Hospital
Dr. Glynn earned a PhD in mathematics and an ScD in biostatistics. He is a Professor of Medicine at Harvard Medical School, Associate Professor of Biostatistics at HSPH, and a Biostatistician in the Divisions of Preventive Medicine, and Pharmacoepidemiology and Pharmacoeconomics, at Brigham and Women’s Hospital. He has been responsible for the design, interim monitoring, and analysis of numerous multi-center randomized trials, funded by the NIH, foundations, and industry, including JUPITER, PREVENT, VAL-MARC, HEART, and the ongoing CIRT trial, other large trials conducted by mail such as the Physicians’ Health Study II, and cluster-randomized trials of interventions such as academic detailing and other strategies to improve the quality of prescribing and adherence, such as the MI FREEE trial. His interim monitoring reports provided the key information that led to the decisions by independent data and safety monitoring boards to terminate both the PREVENT trial (NEJM 2003) and the JUPITER trial (NEJM 2008) because of convincing evidence of benefit to the enrolled participants, and to modify the duration of the MI FREEE trial (NEJM 2011).
Dr. Glynn has also led both randomized and observational studies that have clarified the shared and distinct risk factors and possible preventive approaches for venous and arterial thrombosis, including observational comparisons of the associations of dietary factors and other cardiovascular risk factors with incident venous thromboembolism, as well as randomized trials of the impact of aspirin, vitamin E, and statins on the incidence of venous thromboembolism.
MA: Boston College
PhD: Brandeis University
SM: Harvard School of Public Health
ScD: Harvard School of Public Health
- Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, DeitcherSR, Cushman M, Moll S, Kessler CM, Elliottt CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JA, Bounameaux H, Glynn RJ. Long-term, low-intensity warfarin therapy for the prevention of recurrentvenous thromboembolism. N Engl J Med 2003; 348:1425-1434.
- Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM Jr, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
- Gaziano JM, Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, Schvartz M, Manson JE, Glynn RJ, Buring JE. Multivitamins in the prevention of cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA 2012; 308: 1871-80. PMCID: PMC3517179.
- Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E, Gupta M, Clearfield M, Libby P, Hasan AA, Glynn RJ, Ridker PM. Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013; 166: 199-207.e15. PMCID: PMC3888829.
- Glynn RJ, Lunt M, Rothman KJ, Poole C, Schneeweiss S, Sturmer T. Comparison of alternative approaches to trim subjects in the tails of the propensity score distribution. Pharmacoepidemiol Drug Saf. 2019;28(10):1290-8.DOI: 10.1002/pds.4846PMID: 31385394